All posts tagged
Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease
The Patent Office has Spoken: What does it Mean for CRISPR in Europe?
UPDATE: No Clear Winner in the CRISPR Patent Battle
CRISPR Patent war to End after the Discovery of a New Editing Protein other than Cas9?
Desktop Genetics bags €1.87M from top UK business angels to change how you manage your CRIPSR experiments
CRISPR Therapeutics reinforces its Team with Top Executives from Pfizer and McKinsey
CRISPR Therapeutics opens strategic R&D office in Boston to win the CRISPR war
Live from Bio-Europe 2015: The product development challenges in the gene therapy field
Labiotech UG, All Rights Reserved -
Send this to friend